Science 37 Becomes First FDA-Inspected Site to Deliver Clinical Trials to Patients’ Homes

MORRISVILLE, NC / ACCESS Newswire / February 12, 2026 / Clinical trials are the research studies required to test the ...
Yahoo Finance

Science 37 Appoints Kelly Johnston McKee as VP of Strategy & Transformation

MORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Science 37, the leader in expanding patient access to clinical trials, today announced the appointment of Kelly Johnston McKee as Vice President, ...
Business Facilities

Science 37 To Relocate HQ To Research Triangle Region

Science 37, Inc. will relocate its corporate headquarters from Culver City, CA to North Carolina’s Research Triangle region and create 250 jobs over five years. The clinical research company will ...
Nasdaq

Science 37 to Become Publicly Listed via Merger with LifeSci Acquisition II Corp., Powering the Clinical Trial Operating System of the Future

Transaction values Science 37 at an enterprise value of approximately $1.05 billion at closing Positions Science 37 with a balance sheet of up to $250 million to fund its decentralized trial ...
Business Insider

Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment

RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc., the clinical research industry’s leading Metasite TM, today announced the launch of a stand-alone Patient ...
Seeking Alpha

Science 37 Named Market Leader for Global Decentralized Clinical Trials by Frost & Sullivan

RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (SNCE), the clinical research industry-leading Metasite™, today announced that it has been honored with the ...
Nasdaq

Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment

RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (the “Company” or “Science 37”), the clinical research industry’s leading MetasiteTM, today ...
FierceBiotech

Science 37 tapped for Synlogic's phase 3 trial of potential PKU treatment

Science 37 has been tapped to use its virtual clinical trial tech for phase 3 trials of Synlogic’s treatment for the rare genetic metabolic disorder phenylketonuria (PKU). Under the deal, Science 37’s ...